Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04648475

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Sponsor: Chongqing Precision Biotech Co., Ltd

Conditions Leukemia, B-cell Lymphoma, B-Cell

Interventions CD19 and CD22 targeted CAR-T cells

Updated 6 times since 2021 Last updated: Apr 16, 2023 Started: Aug 25, 2020 Primary completion: Dec 31, 2023 Completion: Jul 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04648475, this PHASE1/PHASE2 trial focuses on Leukemia, B-cell and Lymphoma, B-Cell and remains ongoing. Sponsored by Chongqing Precision Biotech Co., Ltd, it has been updated 6 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Apr 2025 — Present [monthly]

Unknown PHASE1/PHASE2

Status: Recruiting → Unknown
Sep 2024 — Apr 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2023 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Apr 2021 — May 2023 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Aug 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chongqing Precision Biotech Co., Ltd

Data source: Chongqing Precision Biotech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chongqing, China